Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis

Roche Holding AG

The number of gene therapy candidates is expected to skyrocket in the near future.

FDA Expects Explosion in Gene Therapy Treatments, Updates Review Policy

Sarepta Versus The FDA, And Other News: The Good, Bad And Ugly Of Biopharma

Shares of SRPT stock toppled Thursday after U.S. regulators unveiled the concerns that led them to initially reject Sarepta Therapeutics' newest Duchenne muscular dystrophy drug, Vyondys 53.

Sarepta Snagged After FDA Sheds Light On Its Initial Drug Rejection

Despite receiving approval, new documents show that the FDA wasn't entirely convinced about the safety of this treatment for Duchenne muscular dystrophy.

FDA Documents Show Safety Concerns Over a Sarepta Drug

Investors need to pay close attention to Sarepta (SRPT) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Sarepta (SRPT) Stock?

Casimersen Is A Lead Catalyst For Sarepta Therapeutics As A Top 2020 Stock Pick

CAMBRIDGE, Mass., Jan.  13, 2020  (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C. Martin, Ph.D., to its Board of Directors, effective today. Dr. Martin brings decades of executive leadership to Sarepta’s board, having played an instrumental role in building one of the world’s foremost biotechnology companies. During his 20-year tenure as chief executive officer of Gilead Sciences, he oversaw the growth of the company and development of its scientific portfolio into 24 marketed products.

Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors

Biogen

Bristol-Myers

Eli Lilly

Neurocrine Biosciences

Regeneron Pharmaceuticals

If biotech stocks were red hot at the end of 2019, expect them to be scorching next week.

Red-Hot Biotech Stocks Brace For Key Meeting — Here's What To Expect

CAMBRIDGE, Mass., Dec.  31, 2019  (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2019, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to three individuals hired by Sarepta in December 2019. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics  Announces  Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street has high hopes for this mid-cap biotech in the coming year.

Can Sarepta Therapeutics Stock Beat the Broader Markets in 2020?

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares jumped last week on news that the company reached a licensing deal with Roche.

Why One Analyst Sees Sarepta’s Roche Deal Taking Off

Sarepta: Roche Partnership After The FDA's Turnaround Forms The Basis For A $158.59 Near-Term Price Target

Sarepta Therapeutics: Continued Progress In Duchenne MD

Sarepta Therapeutics Inc (NASDAQ: SRPT) has entered a partnership with Roche (OTC: RHHBY) to commercialize SRP-9001, its gene therapy for Duchenne Muscular Dystrophy, outside of the U.S.

Analysts: Roche Partnership Derisks Sarepta Investor Concerns

Sarepta (SRPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Sarepta (SRPT) Looks Good: Stock Adds 7.5% in Session

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares made a handy gain to start the week after it announced a licensing agreement with Roche.

Why This Duchenne Muscular Dystropy Deal Could Be Huge

Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latter's investigational gene therapy asset SRP-9001 outside of the U.S.

Sarepta, Roche Strike Gene Therapy Licensing Agreement Worth Up To $2.85B

Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion.

Sarepta Signs Gene Therapy Agreement With Roche for $1.15B

Roche Holding AG  made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's  investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States.

Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal

– Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States –

Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001

Alector Inc

Amgen

Fulcrum Therapeutics Inc

Ultragenyx Pharmaceutical

Schnitzer Steel Industries Inc

SAGE Therapeutics

Vertex Pharmaceuticals

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.

8 Biotech Stocks Morgan Stanley Recommends For 2020

Sarepta Therapeutics: FDA Approval Reinstalls Confidence In The Pipeline

The FDA's approval of a second Duchenne muscular dystrophy drug brings Sarepta one step closer to market leadership.

FDA's About-Face on Sarepta Drug Lifts Its Stock Out of the Doldrums

Wave Life Sciences stock crashed Monday after the biotech company scrapped development of two Duchenne muscular dystrophy treatments. The decision will benefit rival Sarepta Therapeutics.

Why This Biotech's 50% Plummet Will Undoubtedly Benefit Sarepta

Once Shunned For Marketing Approval, Golodirsen Is Now A Major Win For Sarepta

News for Sarepta Therapeutics Stock (SRPT)